Large phase III clinical trials investigating monoclonal antibodies against PCSK9 to lower serum LDL similarly have not demonstrated any adverse hepatic side effects[59–60], though PCSK9 mutations may exacerbate liver disease in those with PNPLA3 and TM6SF2 mutations[61]. The gene discussed is PNPLA3; the disease is liver disorder.